CymaBay reports positive phase 2 data for seladelpar in patients with PBC
CymaBay Therapeutics reported positive results from its Phase 2 study of seladelpar in a subset of cirrhotic patients with primary biliary cholangitis. Seladelpar is a potent and selective PPARδ agonist currently in development for PBC and NASH. April 12, 2019